IDYA

Ideaya Biosciences Inc

IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) was the target of some unusual options trading on Monday. Investors bought 24,287 call options on the stock. This represents an increase of 2,391% compared to the average volume of 975 call options...

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate...

Wedbush reissued an "outperform" rating and issued a $52.00 target price on shares of IDEAYA Biosciences in a research report on Tuesday...

Tudor Investment Corp ET AL bought a new stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 37,595 shares of the com...

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs...

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire SOUTH SAN...

IDEAYA Biosciences (NASDAQ:IDYA) Trading Down 6.1% - What's Next...

IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) was the target of unusually large options trading on Monday. Investors purchased 9,704 put options on the stock. This is an increase of 1,197% compared to the typical daily volume of 748 put options...

IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial IDEAYA Biosciences Upcoming Investor Relations Events and...